Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multicenter Study of Buntanetap in Participants With Mild to Moderate Alzheimer's Disease

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 16 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

13 May 2025 According to an Annovis Bio media release, data from this study were presented at the AD/PDTM 2025 in Vienna.
25 Mar 2025 According to an Annovis Bio media release, the company will take part in AD/PD™ 2025, taking place April 1-5 in Vienna, and At this meeting the company will present comprehensive data from our latest Phase 3 PD and Phase 2/3 AD studies.
15 Oct 2024 According to an Annovis Bio media release, the company announced the successful outcome of the End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) on October 10, 2024. During the meeting, the FDA granted clearance to proceed with pivotal Phase 3 studies.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com